Abstract
6 children maintained on chronic haemodialysis (4M, 2F age range 3y 11m-14y 10mi) have been entered into a study to establish the efficacy and safety of recombinant human erythropoietin (rHuEPO) in the treatment of anaemia due to end-stage renal disease (ESRD).
rHuEPO has been given in an escalating dose regimen, 3x weekly by IV injection at the end of each dialysis. Efficacy has been assessed by 3x weekly blood counts including reticulocytes (retics), monthly determinations of HLA antibodies and assessments of cardiovascular status and quality of life before commencing rHuEPO and 4 weeks after reaching target haemoglobin {Hb). Biochemical profiles have been checked weekly and iron status assessed monthly.
The first 2 patients studied have responded with increased retic counts and Hb levels. (Pt 1, baseline values; mean Hb 6.3gm/dl, % retics 0.72%, absolute retics 15×109/l; 7th week of rHuEPO; mean Hb 7.4gm/dl, retics 3.05%, absolute retics 72×109/l. Pt 2, baseline values; mean Hb 7.5gm/dl, % retics 1.83%, absolute retics 40×109/l; 7th week of rHuEPO; mean Hb 8.3gm/dl, retics 2,49%, absolute retics 79×109/l). These preliminary results indicate that rHuEPO is effective in correcting anaemia in children with ESRD & will be of benefit.
Article PDF
Rights and permissions
About this article
Cite this article
Rigden, S., Montini, G., Morris, M. et al. 82 RECOMBINANT HUMAN ERYTHROPOIETIN IN THE TREATMENT OF ANAEMIA IN CHILDREN WITH END-STAGE RENAL FAILURE MAINTAINED BY HAEMODIALYSIS. Pediatr Res 24, 274 (1988). https://doi.org/10.1203/00006450-198808000-00108
Issue Date:
DOI: https://doi.org/10.1203/00006450-198808000-00108